Nieva Shares Background on the IMpower010 Study
Jorge Nieva, MD, discusses the backgroup to the IMpower010 study, the results of which were presented at the 2021 American Society of Clinical Oncology Annual Meeting.
Jorge Nieva, MD, of USC Norris Comprehensive Cancer Center, discusses the backgroup to the IMpower010 study (NCT02486718), the results of which were presented at the 2021 American Society of Clinical Oncology Annual Meeting.
According to Nieva, there has been a revolution in immunotherapy in the last decade. The Nobel Prize was awarded for the discovery of checkpoint inhibitors, which, according to Nieva, were able to effect cures in previously incurable patients with advanced disease.
Due to the success of immunotherapy in later line stages of disease, efforts have been made to see if these agents are efficacious in earlier lines and earlier stage disease.
According to Nieva, IMpower010 found the chance of replace was reduced with immunotherapy. However questions around if these agents should be used in earlier lines or if they should be reserved for later remain.
Intracranial Response Data Supports Use of Brigatinib in ALK+ NSCLC
April 26th 2024During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed the intracranial efficacy of brigatinib from the ALTA-1L trial for patients with ALK+ non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
